Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO21 Expert Video Report on HER2-positive early breast cancer

Reporting from the ESMO Congress 2021, Valentina Guarneri provides an overview of the meta-analysis data in HER2-positive early breast cancer from the neoadjuvant trastuzumab-lapatinib studies with regard to the risk of relapse and death and the optimal treatment duration of adjuvant trastuzumab. She also explores the prognostic value of immune gene-expression signatures and TILs to predict the pathological response and patient outcomes.

117O - Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomised trials - Prof Valentina Guarneri, IT
LBA11 - Individual patient data Meta-Analysis of 5 Non-Inferiority RCTs of Reduced Duration single agent adjuvant Trastuzumab in the treatment of HER2 positive Early Breast Cancer - Prof Helena Earl, GB
120MO - Prognostic value of immune gene-expression signatures (iGES) vs. tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: a combined analysis of CALGB 40601 (C40601) and PAMELA trials. - Ms. Aranzazu Fernandez-Martinez, US

This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.